Autoimmune phenomena as prognostic markers of response to adjuvant interferon therapy for melanoma.
Puente Vázquez
J
J
González Larriba
J L
JL
D001323:Autoantibodies / Q000097:blood; D001327:Autoimmune Diseases / Q000139:chemically induced; D015551:Autoimmunity; D017024:Chemotherapy, Adjuvant; D017326:Clinical Trials, Phase III as Topic / Q000706:statistics & numerical data; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006801:Humans; D007107:Immune System / Q000187:drug effects; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D011379:Prognosis; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000139:chemically induced; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D013971:Thyrotoxicosis / Q000139:chemically induced; D014820:Vitiligo / Q000139:chemically induced
D001323:Autoantibodies; D016898:Interferon-alpha